AMARIN CORP. PLC REG.SHS(SP.ADRS NEW)/1 LS-,50 (WK

https://globenewswire.com/news-release/2019/01/23/...fic-Session.html
 

3 Stocks That Are Absurdly Cheap Right Now
[Motley Fool]
George Budwell, Keith Noonan, and Jeremy Bowman, The Motley Fool
,Motley Fool•January 23, 2019

After one of the longest bull markets in history, stocks finally began to revert to the mean late last year, and many did so in a big way. The upside, though, is that this pronounced marketwide downturn created a number of outstanding buying opportunities for investors with a long-term mind-set.

With this theme in mind, we asked three of our Motley Fool contributors which stocks they think are flat-out bargains in the wake of this indiscriminate sell-off. They picked Amarin (NASDAQ: AMRN), Baidu (NASDAQ: BIDU), and Tailored Brands (NYSE: TLRD). Read on to find out why.  
Man in a suit bending a downward trending red line upward.
Man in a suit bending a downward trending red line upward.

Image source: Getty Images.
The luck of the Irish

George Budwell (Amarin): Unlike most other biotech stocks, shares of the Irish biopharma Amarin actually performed quite well in 2018. Over the last 12 months, for instance, the biopharma's shares have appreciated by a jaw-dropping 334%. Even so, Amarin's red-hot stock still has a long way to go before it can be considered expensive or even fairly valued for that matter.

What's the scoop? Amarin's shares took flight late last year following a positive readout for the company's prescription fish oil pill, Vascepa, in a large cardiovascular outcomes trial called Reduce-It. Reduce-It's favorable top-line results attracted investors in droves for two underlying reasons.

First and foremost, Vascepa now appears like it could be a straightforward and cost-effective way to significantly decrease mortality rates among patients with stubbornly high triglyceride levels. As proof, Vascepa reportedly retails for $349 for a 30-day supply, which pales in comparison to the cost of an extended hospital stay stemming from a heart attack or stroke.  

Secondly, Vascepa has the potential to enter one of the largest and most lucrative markets in all of healthcare following these stellar late-stage trial results. Several of the best-selling medications of all time, after all, target patients prone to developing cardiovascular disease. So, while Vascepa's current peak sales projection of $2.5 billion is certainly nothing to sneeze at, this novel fish oil pill may even go on to surpass this stately sales estimate within the next five to 10 years.

Bottom line: Amarin seems destined to continue its recent growth spurt, thanks to Vascepa's outstanding top-line results in REDUCE-IT. As such, bargain-hunters might want to scoop up some shares soon.  

https://seekingalpha.com/article/...ear-timeframe-70-percent-downside  

Der ist nicht negativ eingestellt sondern ein basher und Faktenverdreher, dem wurde die Arztlizenz entzogen und jetzt ist er ein armseeliges Vehicel der shorts....lächerlich!  

Amarin: A Rebuttal To Omega-3 Fans

Jan. 30, 2019 3:55 PM ET|61 comments | About: Amarin Corporation PLC

... (automatisch gekürzt) ...



 

https://seekingalpha.com/article/...amarin-rebuttal-omegaminus-3-fans

 

 

Neue Rekordverschreibungszahlen:

TRx: 37,934{vs 36,875;+2.87%}Sec+0.27% ATH NRx: 17,624{vs 16,563;+6.41%}Sec+2.34% ATH Ref: 20,310{vs 20,312;-0.01%}Sec-1.36% 2ndATH  

Novartis (NVS) Rumored to Be in Talks to Acquire Amarin (AMRN) - Source
February 22, 2019 9:59 AM
Novartis (NYSE: NVS) is rumored to be in talks to acquire Amarin Corp. (NASDAQ: AMRN), according to a source claiming ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)  

 

 

Vllt schon diesen Monat  

Amarin meldet Zahlen für 2018

• Umsätze 229 Mio. $ (vgl. 181)
  
• Verlust 116 Mio. $ (vgl. 68)
  

"2019 Revenue: Net total revenue for 2019 is anticipated to increase by more than 50% over 2018 to approximately $350 million, mostly from U.S. sales of Vascepa.  Amarin believes that continued quarterly variability in revenues is likely. This guidance assumes that the timing of the expanded label for Vascepa which Amarin is seeking, subject to FDA approval, will not be available until late 2019 or early 2020 such that the expanded label has little or no impact on revenue growth in 2019."

https://investor.amarincorp.com/news-releases/...r-and-full-year-2018

 

 

Mega news, Vascepa von Amarin von der amerikanischen Diabetiker Organisation als standard of care aufgenommen, Millionen Diabetiker als Zielgruppe:

https://finance.yahoo.com/news/...tes-association-2019-090000025.html  

Amarin meldet Zahlen für Q1/19

• Umsätze 73 Mio. $
  
• Verlust 24 Mio. $
  

https://investor.amarincorp.com/news-releases/...results-and-provides

 

 

https://finance.yahoo.com/news/3-top-mid-cap-stocks-113100104.html  

H.C. Wainwright Survey Shows Substantial Runway For Amarin Corporation's (AMRN) Vascepa
June 26, 2019 8:21 AM
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $51.00 price target on Amarin Corporation (NASDAQ: AMRN) after conducted ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
 

Vascepa Update & Anhebung der Umsatzprognose

• Q2/19 Umsatzausblick 97-101 Mio. $
  
• H1/19 Umsatzprognose 170-174 Mio. $
  
• für 2019 wird die Umsatzprognose von 350 Mio. $ auf 380-420 Mio. $ angehoben
  

https://investor.amarincorp.com/news-releases/...ng-commercialization

 

Why Amarin Stock Is Up 63% So Far in 2019
[Motley Fool]
Beth McKenna, The Motley Fool
,Motley Fool•July 10, 2019
What happened

Shares of Irish biotech Amarin (NASDAQ: AMRN) are up 14.2% so far this month, through Tuesday, July 9.

This rise follows the stock's 42.5% gain in the first half of 2019, according to data from S&P Global Market Intelligence. The S&P 500 returned 18.4% over this period.

Amarin's year-to-date gain is a hearty 62.7% through July 9, versus the broader market's 20.2% return.
A pile of six see-through, light-gold capsules on a flat surface.
A pile of six see-through, light-gold capsules on a flat surface.

Image source: Getty Images.
So what

July

On July 2, Amarin shares surged 16.3% following the company increasing its full-year 2019 revenue guidance to a midpoint of $400 million, up from $350 million. The raise was driven by strong demand for Vascepa, its omega-3 fatty-acid drug derived from fish oil that's currently approved to treat patients with high triglyceride levels.

This demand could be only a start, however, as Amarin and its investors are eagerly anticipating the U.S. Food and Drug Administration's decision on a huge label expansion. In late September, investors should learn whether the FDA has given the green light to Vascepa for the treatment of patients at risk for major adverse cardiovascular events, including heart attacks or strokes.

As background: Amarin stock skyrocketed last September after the company released robust results of its Reduce-It cardiovascular outcomes study. As I previously wrote, "The study showed that Vascepa ... reduced the risk of major adverse cardiovascular events by 25% in patients already taking statin drugs compared to those receiving a placebo, which is a highly statistically significant result."

AMRN Chart
AMRN Chart

Data by YCharts.

First Half of 2019

Amarin stock likely got a tailwind in the first half of the year from the strong overall market. That said, we can attribute its outperformance of the market to several catalysts, including:

   Jan. 9: Shares popped 8.1% following the company's optimistic presentation at the J.P. Morgan Healthcare Conference.
   Jan. 10: Shares soared 22.1% on market chatter about pharmaceutical giant Pfizer being interested in making a bid for Amarin.
   Feb. 22-27: Shares gained 21.5% in the four market days leading up to and including the company's release of its fourth-quarter and full-year 2018 results, driven by investor optimism about Vascepa sales on the heels of the Reduce-It study. Indeed, investors were right to be hopeful, as Vascepa's Q4 revenue rose 44% year over year to $77.3 million.
   May 29: Shares surged 11.6% after Amarin announced that the FDA had granted an expedited review of Vascepa for patients at risk of major adverse cardiovascular events. This moved the timetable for the agency's decision to six months after the application submission rather than the more usual 10 months.

Now what

Take heart, investors: The FDA's decision on Vascepa's label expansion should be less than three months away, in late September. Look for Amarin stock to react accordingly.  

400 Mio. $ ADS Offering

• 22,22 Mio. ADS´s zu je 18$
  

https://investor.amarincorp.com/news-releases/...-depositary-shares-3

 

Amarin up 3% premarket on draft ICER report confirming Vascepa value
Jul. 24, 2019 9:07 AM ET|About: Amarin Corporation plc (AMRN)|By: Douglas W. House, SA News Editor

Amarin (NASDAQ:AMRN) perks up 3% premarket on light volume on the heels of a draft report from the non-profit Institute for Clinical and Economic Review (ICER) concluding that Vascepa (icosapent ethyl) and Johnson & Johnson's (NYSE:JNJ) blood thinner Xarelto (rivaroxaban) provide clinical benefit, reduce cardiovascular risk and "fall below commonly cited thresholds for cost-effectiveness." In other words, the products are priced appropriately for the value delivered.

JNJ is off a fraction premarket.

See all stocks on the move »  

Amarin Is Just Running Up That Hill; Peak Sales Could Reach $10B, Says Analyst
[TipRanks]
TipRanks
,TipRanks•July 24, 2019

Biotech Amarin (AMRN) is one of Wall Street’s biggest standouts, with shares skyrocketing 566% in just the last year. Its fish-oil derivative drug Vascepa is already clinically proven to lower very high triglycerides without raising bad cholesterol. What’s more, recent trials revealed it could also cut cardiovascular risks by 25% in patients with abnormally high triglyceride levels. The FDA will either approve or reject this potentially very lucrative label expansion on September 28, and approval should send shares soaring.

An approval would make Vascepa the first therapy, as an adjunct to diet, proven to reduce cardiovascular events when used to treat patients with persistent elevated triglyceride levels and other cardiovascular risk factors. It is this large, unmet medical need for potentially tens of millions of patients which Vascepa has been targeting for many years.

Ahead of this key date, Cantor Fitzgerald analyst Louise Chen has just released a very bullish report on Amarin. She made the call following the company's recent equity raise. “The proceeds should help accelerate the growth of Vascepa, and we think the peak sales potential of this drug could be $5B-$10B” writes Chen. FactSet forecasts $2.1B of sales by 2024.

Indeed Amarin currently shows a ‘Strong Buy’ Street consensus with all six analysts covering the stock bullish. Meanwhile the average analyst price target of $33 suggests shares can surge over 80% from current levels.

On July 18, AMRN announced the pricing of the underwritten public offering of 22.2 million shares at a price of $18 per shares. The gross proceeds of this offering are expected to be ~$400 million, before deducting expenses. Note that Amarin has also granted the underwriters a 30-day option to purchase up to an aggregate of 3.3 million additional shares.

As the company’s press release reveals, AMRN intends to use the net proceeds from the offering for multiple purposes. These include: (1) doubling its existing sales force for Vascepa to 800, increasing advertising, and supporting expanded commercial operations; (2) increasing the commercial supply of Vascepa from third-party drug product suppliers; and (3) for general corporate purposes.

“Amarin also may use a portion of the net proceeds to acquire strategic assets, although it currently has no agreements or commitments in this regard” the statement says.

Looking ahead the next catalysts to keep an eye on are as follows: 1) as you would expect, the potential FDA approval AMRN's supplemental new drug application (sNDA) seeking an expanded indication for Vascepa in the US based on the positive results of AMRN's REDUCE-IT study, 2) pick up in sales from expanded label as well as increased sales and promotional efforts, and 3) Amarin becoming profitable by 2020 (according to the analyst’s estimate).

Net-net, Chen reiterates her buy rating with a $35 price target (93% upside potential). “We continue to think that AMRN is an interesting asset in a consolidating space” she says.  

• 101 Mio. $ Umsatz in Q2/19
  

https://investor.amarincorp.com/news-releases/...inancial-results-and